Annemarie (A.) van de Geer MD


Medicine; Law

Research interests

(Intensive) chemotherapy can result in a reduced production of white blood cells (immune cells), especially neutrophils. These neutrophils are essential in the defence against bacteria and fungi. Patients with longstanding neutropenia run the risk of developing a life-threatening infection. Administration of neutrophils from healthy donors is an effective way to fight such infections in case antibiotic and/or antifungal therapy fails. However, patients themselves need to recruit these donors, which are subjected to extensive medical screening and dexamethasone/growth hormone (GCSF) therapy. This is a time consuming, cumbering procedure for the patient, family, doctor and donor, with unknown long term effects of the GCSF. Therefore, we are trying to develop a new granulocyte transfusion product, from residual pooled buffy coats, which we will compare to the standard G-CSF/dexamethasone product. Also, we will perform a biomarkerstudy in adult hematology patients in order to refine the timing, indications and eligible patients for granulocyte transfusions.


  • Blood cell isolation
  • Granulocyte function assays
  • Western blotting
  • In vitro microbiocidal killing
  • Flow cytometry


2014-present PhD student at Dept Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands
2013-2014 Registrar pediatrics, Flevoziekenhuis Almere
2011 Research project Dept of Endocrinology, Children’s Hospital Boston, Harvard University, Boston MA, USA
2007-2013 Medicine, University of Amsterdam, Cum Laude
2007-2013 Bachelor of Laws, University of Amsterdam

Other publications

Kleinjan A, Aggarwal A, van de Geer A, Faselis C, Büller HR, Di Nisio M, Rickles FR, Kamphuisen PW. A worldwide survey to assess the current approach to the treatment of patients with cancer and venous thromboembolism. Thromb Haemost 2013; 110(5):959-65.